Efavirenz and CYP2B6 polymorphism: Implications for drug toxicity and resistance by Nolan, D. et al.
408 • CID 2006:42 (1 February) • EDITORIAL COMMENTARY
EDITORIAL COMMENTARY
Efavirenz and CYP2B6 Polymorphism:
Implications for Drug Toxicity and Resistance
David Nolan,
1 Elizabeth Phillips,
2 and Simon Mallal
1
1Centre for Clinical Immunology and Biomedical Statistics, Murdoch University and Royal Perth Hospital, Perth, Australia; and
2British Columbia Centre for Excellence
in HIV/AIDS, University of British Columbia, Vancouver, Canada
(See the article by Ribaudo et al. on pages 401–7)
Received 24 October 2005; accepted 25 October 2005;
electronically published 27 December 2005.
Reprints or correspondence: Dr. Simon Mallal, Centre for
Clinical Immunology and Biomedical Statistics, Murdoch
University, Royal Perth Hospital, 2nd Flr., North Block, Perth,
WA 6000, Australia (s.mallal@murdoch.edu.au).
Clinical Infectious Diseases 2006;42:408–10
  2005 by the Infectious Diseases Society of America. All
rights reserved.
1058-4838/2006/4203-0019$15.00
The brief history of pharmacogeneticshas
been marked by a high level of public as
well as professional interest, reﬂecting in
many respects the great promise offered
by genomic approaches to biology,clinical
medicine, and pharmacologyoverthepast
∼15 years. This early interest in person-
alized medicine was fueled by reviews [1,
2] in which it was predicted that drug pre-
scribing could be undertaken with greater
certainty and objectivity after elucidation
of genetic traits determining variabledrug
disposition between individuals. The
noted geneticist Allen Roses raised the
ghost of Sir William Osler in his contem-
plation of the quote “If it were not for the
great variability among individuals, med-
icine might as well be a science and not
an art” (p.857) [2]. Roses’ response, made
just over one hundred years later (in
2000), hinted that the end was in sight for
the art of medicine, offering that “…we
are on the verge of being able to identify
inherited differences between individuals
which can predict each patient’s response
to a medicine. This ability will have far-
reaching beneﬁts in the discovery, devel-
opment and delivery of medicines” (p.
857) [2].
Now, more than 5 years after these ob-
servations, it is clear that much has been
learned about the genetics of drug metab-
olism and drug disposition, and it is true
that pharmacogenetic approaches to drug
prescribing have proven to be selectively
useful in improving drug safety and efﬁ-
cacy. One widely cited example, genetic
testing for loss-of-function variants of
thiopurine S-methyltransferase to prevent
severe dose-dependent azathioprine drug
toxicities (e.g., pancytopenia), has proven
to be widely utilized in a recent survey of
pharmacogenetic testing [3, 4]. However,
when measured collectively in terms of
their clinical application, these successes
have remained relatively few in number.
To some extent, this reﬂects an increased
appreciation of the inherent complexityin
predicting drug metabolism on the basis
of single genetic traits [5], given that (1)
drugs often employ multiple mechanisms
of activation and catabolism, (2) genetic
variation is often determined at multiple
sites and/or haplotypic combinations of
alleles within a gene of interest and can
also be inﬂuenced by complex transcrip-
tional signaling pathways, and (3) drug
metabolism is often stronglyinﬂuencedby
the coadministration of prescribed, rec-
reational, or herbal drugs. These issues are
particularly relevant in the ﬁeld of HIV
medicine [6], in which antiretroviral reg-
imens include combinations of drugs
from multiple drug classes and there is
frequent coprescription of anti-infective
drugs, as well as frequent use of nonpres-
cribed medications by patients.
It is with this history in mind that we
turn our attention to the implications of
a recent study investigating associations
between a cytochrome P450 2B6 gene
(CYP2B6) polymorphism and efavirenz
metabolism, presented by Ribaudo et al.
[7] as part of an analysis of the AIDSClin-
ical Trials Group studies A5095 and
A5097s in this issue of Clinical Infectious
Diseases.Thisstudyisimportantandtimely
in that it not only encompasses many of
the practical issues raised by pharmacoge-
netic research but also identiﬁes issues par-
ticularly pertinent and unique to the use of
antiinfectives, as well as highlighting issues
relevant to the clinical applicability of ge-
netic testing. CYP2B6 is genetically poly-
morphic and is implicated in the metab-
olism of a growing number of clinically
important drugs (∼8% of drugs on the
market are metabolized by CYP2B6). This
cytochrome P isoform is the main catalyst
of efavirenz metabolism (to its inactive 8-
OH metabolite), suggesting that polymor-
phisms in CYP2B6 may have major impli-
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nonnucleoside reverse-transcriptase inhib-
itor (NNRTI) drug [8], which is currently
recommended as an option for ﬁrst-line
combination therapy for HIV infection[9].
These authors have previously identi-
ﬁed a CYP2B6 genotype (G516T) associ-
ated with slow clearance and high plasma
levels of efavirenz [8]. This association is
not trivial, and, although it is clear that
there is a degree of overlap between in-
dividuals who are homozygous for the
variant allele (516T) and the remainder of
the population in terms of efavirenzlevels,
it is also apparent that the most important
clinical toxicities associated with efavirenz
use are dose dependent (at least in part)
and are therefore inﬂuenced by the phar-
macogenetics of CYP2B6 polymorphism.
This appears to be true for the CNS-re-
lated side effects of this drug (typically in-
volving sleep disturbance, difﬁculties with
concentration, and increased anxiety and/
or depression in a subset of individuals),
as demonstrated in an AIDS ClinicalTrials
Group–sponsored clinical trial [8] and in
a Swiss HIV cohort [10]. Therefore, car-
riage of the deleteriousCYP2B6516TTge-
notype by ∼3% of whites and ∼20% of
blacks appears to predict a more compli-
cated course of treatmentandahigherrisk
of toxicity-driven drug discontinuation.
CYP2B6 polymorphisms have also been
reported (e.g., K262R) that may also con-
tribute to variable enzyme function and
further delineate high-risk genotypes[11],
suggesting that CYP2B6 variation may re-
ﬂect a more complex set of genetic traits.
In this study [7], the authors have hy-
pothesized that a slow decay of efavirenz
levels after combination antiretroviral
therapy is discontinued can lead to the
emergence of drug resistance to the entire
class of NNRTI drugs. This clearly hasim-
portant and widespread implications for
antiretroviral treatment in resource-poor
settings, where the prevalence of the
CYP2B6 516 TT genotype is high, treat-
ment options are limited, and treatment
has relied heavily on nevirapine in single-
dose perinatal prophylaxis and, more re-
cently, on nevirapine as part of ﬁxed-dose
combinations with nucleoside analogues.
This argument has a sound theoreticalba-
sis, because(1) theNNRTIdrugsefavirenz
and nevirapine, both of which are metab-
olized by CYP2B6, are characterized by a
low genetic barrier to resistance, so that a
single mutation within the reverse-tran-
scriptase sequence (e.g., K103N) can con-
fer high-level drug resistance andpreclude
anyfurtheruseofcurrentlylicensedmem-
bers of this drug class, and (2) efavirenz
has a very long terminal half-life, and pre-
vious studies have suggested that it may
be present as monotherapy 2–3 weeks or
longer after drug discontinuation[12,13].
A recent case report highlights the poten-
tial for acquired drug resistance in a
woman who stopped taking efavirenz
without guidance and had detectabledrug
levels 8 weeks after discontinuation of
therapy. Of interest, she was heterozygous
for the G516T polymorphism and was
wild type for other CYP2B6 polymor-
phisms [13].
In this study [7], the induction and
steady-state levels of efavirenz in study
A5097s were assessed (with the exception
of 1 case patient from the aborted A5131
study, for whom data from treatment dis-
continuation could be assessed directly),
and rates of efavirenz clearance were sub-
sequently estimated on the basis of these
results. It is therefore important to ac-
knowledge that the data relating to efa-
virenz clearance after discontinuation of
therapy are derived (ratherthanobserved)
values. The points that are made are still
important and valid, although the as-
sumptions made in the pharmacokinetic
analyses (i.e., a 1-compartment model
withﬁrst-orderabsorption)maydiffersig-
niﬁcantly from observed data (i.e., the 2-
compartment model describedfortheone
A5131 study participant). The main re-
ported result was that 150% ofindividuals
with the CYP2B6 516 TT genotype had
persistently detectable drug levels (sufﬁ-
cient to favor the development of drug
resistance) for 121 days. However, perusal
of the data also points tothe factthatthere
was a wide distribution of drug levels in
each CYP2B6 genotype group, so that
there is no clear delineation of a patient
group in which efavirenz can be safelydis-
continued without risk of inducing
resistance.
Are there any clinical practice points
that may be derived from these data? To
some extent, the ﬁndings from this study
reinforce a view of drug prescribing that
is closer to Dr. Osler’s reckoning than to
Dr. Roses’, although the“art”ofmanaging
efavirenz treatment can certainly be in-
formed by the observations that drug dis-
position is inherently variable between in-
dividuals (due to genetic variation) and
that this variation may have signiﬁcant
impact on drug toxicity and on the de-
velopment of drug resistance when treat-
ment withdrawal is unplanned. In terms
of current practice, we can imagine 3
proactive scenarios that could be consid-
ered further to minimize both drug tox-
icity and the potential for drug resistance:
1. The current standard of care, in
which all patients receive a 600-mg dose
of efavirenz once per day, with clinical
monitoring and carefulcounselingregard-
ing unplanned interruption. This ap-
proach would also plan for coverage with
alternative antiretroviral therapy (e.g.,nu-
cleoside reverse-transcriptase inhibitor
and protease inhibitor regimens) for
planned drug interruptions.
2. Use of therapeutic drug monitor-
ing in deﬁning the “slow metabolizer”
phenotype so that dose reduction may be
considered. This approach may also alle-
viate drug toxicity and improveadherence
to therapy. In this scenario, dose adjust-
ment should make the issue of prolonged
NNRTI decay less signiﬁcant, and thera-
peutic drug monitoring would still be a
useful tool for monitoring the need for
alternative HIV drug coverage following
discontinuation of therapy with NNRTIs.
3. Use of a combination of CYP2B6
genotyping and therapeutic drug moni-
toring to direct therapy. With this ap-
proach, “high risk” CYP2B6 genotypes





























































































 410 • CID 2006:42 (1 February) • EDITORIAL COMMENTARY
those individuals who might beneﬁt most
from therapeutic drug monitoring early,
with a view to dose adjustment.
At present and in the absence of further
evidence, it would seem to be prudent to
take a broad approach to the issue, as out-
lined in the ﬁrst scenario described above.
It remains to be determined whether a
pharmacogenetic approach could (or
should) be used to identify patients who
arelikelytobeneﬁtmorefromappropriate
protease inhibitor–based therapy as a pri-
marytreatmentoption(avoidingefavirenz
because of the high risk of treatment tox-
icity), particularlywithinpopulationswith
a higher frequency of deleterious geno-
types. However, it is these same popula-
tions at risk that are currently overrepre-
sented in resource-poor settings, where
NNRTI-based treatment may be the only
option. Therefore,thisagainhighlightsthe
need for more research to deﬁne both fea-
sible and optimal treatment and discon-
tinuation strategies. At this stage, such
studies—like much of pharmacogenetics
research and clinical application—remain
resolutely in the future.
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